| Perturbation type | Gene | Citation | Cancer type | Gene-disease relation |
|---|---|---|---|---|
| Top gains | RNF146 (Isoform switch) | 15994935 | KIRP | Differentially expressed in KIRP patients compared to expression profiles in noncancerous kidney cortical samples |
| Top gains | SH3BP2 (Isoform switch) | 15994935 | KIRP | Differentially expressed in KIRP patients compared to expression profiles in noncancerous kidney cortical samples |
| Top losses | REPIN1 (Isoform switch) | 15994935 | KIRP | Differentially expressed in KIRP patients compared to expression profiles in noncancerous kidney cortical samples |
| Top losses | BCAN (Isoform switch) | 15994935 | KIRP | Differentially expressed in KIRP patients compared to expression profiles in noncancerous kidney cortical samples |
| Top gains | ASB14 | 15994935 | KIRP | Differentially expressed in tumor samples compare to normal samples. |
| Top gains | CCNE2 | 28984208 | KIRC | Stage-specific mRNA biomarker. |
| Top gains | CENPA | 30822312 | KIRP | Significantly associated with the survival time of patients. |
| Top gains | E2F2 | 26967247 | KIRC | Tumor suppressor in ccRCC. |
| Top gains | ESCO2 | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. Renal abnormalities due to Esco2 mutation. |
| Top gains | HJURP | 30988807 | KIRC | Associated with overall survival and recurrence-free survival in ccRCC. |
| Top gains | IGF2BP3 | 30822312 | KIRP | Associated with KIRP patient survival. |
| Top gains | MSX2 | 24332042 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
| Top gains | PBK | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top gains | POLE2 | 23634695 | RCC | Differentially expressed in metastases compared to normal kidney cells. |
| Top gains | POTEF | 30089500 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top gains | SGO1 | 25740822 | Renal transitional cell carcinoma | Sgo1 -/+ mouse has renal transitional cell carcinoma phenotype. |
| Top gains | SKA3 | 29928475 | RCC | Overexpressed in RCC cells. |
| Top gains | TTK | 30822312 | KIRP | mRNA of TTK significantly associated with the survival time of patients. |
| Top cancer-specific gains | ASB14 | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top cancer-specific gains | CCNE2 | 24765202 | RCC | Down-regulated in RCC cell line |
| Top cancer-specific gains | MSX2 | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top cancer-specific gains | POTEF | 30089500 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top losses | ASB5 | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top losses | ATP12A | 26807193 | CRCC | ATP12A missence mutation associated with CRCC. |
| Top losses | CALML3 | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top losses | CLNK | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top losses | DKK1.00 | 24676838 | KIRC | significantly lower in human KIRC than in the healthy controls. |
| Top losses | FBN3 | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples |
| Top losses | FOXI2 | 30089500 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top losses | FOXN1 | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top losses | HEPACAM2 | 31019939 | KIRC | Down-regulated in KIRC samples. |
| Top losses | MYOZ2 | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| Top losses | NOS1 | 15150612 | RCC | Down-regulated in tumor samples compared to normal samples. |
| Top losses | NR0B2 | 27540300 | KIRC | Down-regulated in tumor samples compared to normal samples. |
| Top losses | PRMT8 | 28454353 | Renal cancer | Down-regulated in tumor samples compared to normal samples. |
| Top losses | RALYL | 23428843 | RCC | Differentially hypermethylated genes between chromophobe RCC and renal oncocytoma samples. |
| Top losses | SOX30 | 28029648 | KIRP | Differentially overexpressed in black compared to white pRCC patients. |
| Top losses | TTR | 1879819 | RCC | Differentially expressed |
| Top losses | VSIG2 | 15994935 | KIRP | Differentially expressed in tumor samples compare to normal samples |
| Top cancer-specific losses | DKK1.00 | 20549706 | KIRC | DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. |
| Top cancer-specific losses | MDFI | 15994935 | KIRP | Differentially expressed in tumor samples compared to normal samples. |
| SMGs within edgetic gains or losses | CUL3 | 23365135 | KIRP:sporadic | CUL3 somatic mutation associated with KIRP |
| SMGs within edgetic gains or losses | KMT2D | 15994935 | KIRP | Differentially expressed in tumor samples compare to normal samples. |
| SMGs within edgetic gains or losses | MET | 10327054 | KIRP | MET somatic mutation associated with KIRP. |
| SMGs within edgetic gains or losses | RNF2 | 30269473 | KIRP | RNF2 (BAP1) was differentially expressed in KIRP samples. |
| SMGs within edgetic gains or losses | SMARCB1 | 26536169 | KIRP | SMARCB1 mutation was associated with KIRP. |
To download a file, either filter the gene of interest or select all the entries and then press the "Download as Excel table" button